NASDAQ:RNA

Avidity Biosciences Q1 2025 Earnings Results & Report

Avidity Biosciences logo
$6.43 -1.08 (-14.38%)
As of 04:00 PM Eastern

Avidity Biosciences missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.90 versus the -$0.88 consensus estimate, while revenue of $1.60 million fell short of the $2.63 million estimate by $1.03 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
3:00 AM ET

Avidity Biosciences EPS Results

Actual EPS
-$0.90
Consensus EPS
-$0.88
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Avidity Biosciences Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
$2.63 million
Beat/Miss
Missed by -$1.03 million
YoY Revenue Growth
N/A

Avidity Biosciences Q1 2025 Earnings FAQ

Avidity Biosciences (NASDAQ:RNA) reported earnings of -$0.90 per share for Q1 2025, missing the consensus estimate of -$0.88. The report was announced on Thursday, May 8, 2025.

Avidity Biosciences reported revenue of $1.60 million for Q1 2025, against a consensus estimate of $2.63 million.

Avidity Biosciences Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
Avidity Biosciences (RNA) Expected to Post Earnings on Thursday
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA) is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells.

The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.

View Avidity Biosciences Profile